FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2986952011> ?p ?o ?g. }

• W2986952011 endingPage "5843" @default.
• W2986952011 startingPage "5843" @default.
• W2986952011 abstract "Background: Use of Tyrosine Kinase inhibitors (TKIs) have significantly improved the prognosis of Chronic Myelogenous Leukemia (CML). Since the first clinical use of Imatinib 20 years ago, second generation TKIs have been approved for first line treatment, which include Dasatinib (approved in Nov. 2010), Nilotinib (June 2010) and Bosutinib (Dec. 2017). Ponatinib, a third generation TKI (approved for third line treatment in Dec. 2012), is the only effective TKI in patients with t315i mutation in bcr/abl gene. In this study, we analyzed patient experiences and use of various TKIs in CML patients. Method: Many patients share their experiences in online forums that contain clinically relevant information. However, data is unstructured and hence difficult to analyze. We collected 18.2 million messages from 97 different unrestricted cancer forums, including those 44 that were CML related. We created custom ontology for CML and TKIs regarding their efficacy and side effects. We then used our AI-based platform, VoCP, to analyze these messages by using artificial intelligence techniques, e.g., natural language processing, topic modeling and machine learning. Results: VoCP found 87,555 messages regarding CML from 10,605 unique users. Of these, 4,857 users shared 11,017 messages containing experiences with TKIs. 2,164 users mentioned the use of Imatinib, 819 used Dasatinib, 747 used Nilotinib, 97 used Bosutinib and 71 used Ponatinib. 47 patients mentioned undergoing bone marrow transplant. 1,139 patients mentioned being diagnosed before 2010 and at least 938 of them started with Imatinib. 1,082 patients reported diagnosis between 2010-2017; 357 started with Imatinib, 235 with Dasatinib and 236 with Nilotinib. 163 patients reported diagnosis after 2017; 47 started with Imatinib, 51 with Dasatinib, 27 with Nilotinib and 5 with Bosutinib. Imatinib: Switches: 501 patients switched to Dasatinib, 248 to Nilotinib, 14 to Bosutinib and 7 to Ponatinib. Side effects: 2,164 users mentioned 939 messages with side effects, which included pain 220 (23.4%), myelosuppression 154 (16.4%), fatigue 111 (11.7%), Skin rash (11.6%), GI upset 70 (2.4%), edema 84 (8.9%) heart problems 17, DVT/PE 5 and renal dysfunction 5. Dasatinib: Switches: 60 patients switched from Dasatinib to Imatinib, 79 to Nilotinib, 28 to Bosutinib and 9 to Ponatinib. Side effects: 819 patients shared 587 messages with side effects, which included Myelosuppression 113 (9.2%), rash 87 (14%), headache 78 (12.2%), pain 61 (1.7%), edema 30, Pleural effusion 24 and abdominal pain 11. Nilotinib: Switches: 95 patients switched to Dasatinib, 57 to Imantinib, 13 switched to Bosutinib and 5 to Ponatinib. Side effects: 747 users shared 390 messages with side effects, which included rash 135 (34.6%), pain 62 (15.9%), Myelosuppression 43 (11%), edema 16 (4.1%), cardiac issues 8 (2%), GI issues 13 (3.3%) and abdominal pain 2. Bosutinib: Switches: 1 patient switched from Bosutinib to Imatinib, 4 to Dasatinib, 2 to Nilotinib and 1 to Ponatinib. Side effects: 97 patients shared 39 messages with side effects, which included nausea 9 (23%), Myelosuppression 6(15%), edema 5 (12.8%) and diarrhea 4 (1.1%). Ponatinib: Switches: 3 patients mentioned switching from Ponatinib to Dasatinib, 3 patients to Bosutinib, 2 to Nilotinib, and 1 to Imatinib. Side effects: 71 users shared 25 messages with side effects, which included rash 13 (51%), pancreatitis 1 and fatigue 1. Conclusions: Despite the approval of second generation TKIs, Imatinib is most commonly used for treating CML in first line. MMR and CMR are similar for all TKIs. VoCP reliably provides meaningful insights from the patient's point of view and gives insight into unmet needs where more resources and research should be focused. Table Disclosures Aggarwal: Scry Analytics,Inc: Equity Ownership. Aggarwal:Scry Analytics, Inc.: Equity Ownership." @default.
• W2986952011 created "2019-11-22" @default.
• W2986952011 creator A5003806698 @default.
• W2986952011 creator A5034238598 @default.
• W2986952011 creator A5035657584 @default.
• W2986952011 creator A5043325340 @default.
• W2986952011 creator A5047658966 @default.
• W2986952011 creator A5057230815 @default.
• W2986952011 creator A5087757271 @default.
• W2986952011 date "2019-11-13" @default.
• W2986952011 modified "2023-09-27" @default.
• W2986952011 title "Voice of Cancer Patients: Patient Experience Regarding Use of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia" @default.
• W2986952011 doi "https://doi.org/10.1182/blood-2019-125195" @default.
• W2986952011 hasPublicationYear "2019" @default.
• W2986952011 type Work @default.
• W2986952011 sameAs 2986952011 @default.
• W2986952011 citedByCount "0" @default.
• W2986952011 crossrefType "journal-article" @default.
• W2986952011 hasAuthorship W2986952011A5003806698 @default.
• W2986952011 hasAuthorship W2986952011A5034238598 @default.
• W2986952011 hasAuthorship W2986952011A5035657584 @default.
• W2986952011 hasAuthorship W2986952011A5043325340 @default.
• W2986952011 hasAuthorship W2986952011A5047658966 @default.
• W2986952011 hasAuthorship W2986952011A5057230815 @default.
• W2986952011 hasAuthorship W2986952011A5087757271 @default.
• W2986952011 hasBestOaLocation W29869520111 @default.
• W2986952011 hasConcept C121608353 @default.
• W2986952011 hasConcept C126322002 @default.
• W2986952011 hasConcept C143998085 @default.
• W2986952011 hasConcept C170493617 @default.
• W2986952011 hasConcept C2776960273 @default.
• W2986952011 hasConcept C2777413986 @default.
• W2986952011 hasConcept C2777583451 @default.
• W2986952011 hasConcept C2778208673 @default.
• W2986952011 hasConcept C2778461978 @default.
• W2986952011 hasConcept C2778729363 @default.
• W2986952011 hasConcept C2778820342 @default.
• W2986952011 hasConcept C2779490328 @default.
• W2986952011 hasConcept C2779536868 @default.
• W2986952011 hasConcept C2780381907 @default.
• W2986952011 hasConcept C3019892230 @default.
• W2986952011 hasConcept C42362537 @default.
• W2986952011 hasConcept C71924100 @default.
• W2986952011 hasConceptScore W2986952011C121608353 @default.
• W2986952011 hasConceptScore W2986952011C126322002 @default.
• W2986952011 hasConceptScore W2986952011C143998085 @default.
• W2986952011 hasConceptScore W2986952011C170493617 @default.
• W2986952011 hasConceptScore W2986952011C2776960273 @default.
• W2986952011 hasConceptScore W2986952011C2777413986 @default.
• W2986952011 hasConceptScore W2986952011C2777583451 @default.
• W2986952011 hasConceptScore W2986952011C2778208673 @default.
• W2986952011 hasConceptScore W2986952011C2778461978 @default.
• W2986952011 hasConceptScore W2986952011C2778729363 @default.
• W2986952011 hasConceptScore W2986952011C2778820342 @default.
• W2986952011 hasConceptScore W2986952011C2779490328 @default.
• W2986952011 hasConceptScore W2986952011C2779536868 @default.
• W2986952011 hasConceptScore W2986952011C2780381907 @default.
• W2986952011 hasConceptScore W2986952011C3019892230 @default.
• W2986952011 hasConceptScore W2986952011C42362537 @default.
• W2986952011 hasConceptScore W2986952011C71924100 @default.
• W2986952011 hasIssue "Supplement_1" @default.
• W2986952011 hasLocation W29869520111 @default.
• W2986952011 hasOpenAccess W2986952011 @default.
• W2986952011 hasPrimaryLocation W29869520111 @default.
• W2986952011 hasRelatedWork W1554937972 @default.
• W2986952011 hasRelatedWork W2013963600 @default.
• W2986952011 hasRelatedWork W2037274216 @default.
• W2986952011 hasRelatedWork W2068126251 @default.
• W2986952011 hasRelatedWork W2142609621 @default.
• W2986952011 hasRelatedWork W2155107050 @default.
• W2986952011 hasRelatedWork W2168411181 @default.
• W2986952011 hasRelatedWork W2401908067 @default.
• W2986952011 hasRelatedWork W2782601539 @default.
• W2986952011 hasRelatedWork W3118230164 @default.
• W2986952011 hasVolume "134" @default.
• W2986952011 isParatext "false" @default.
• W2986952011 isRetracted "false" @default.
• W2986952011 magId "2986952011" @default.
• W2986952011 workType "article" @default.